Strategic Partnerships LeonaBio is a clinical-stage biotechnology company with a focus on high unmet medical needs including ALS and treatment-resistant metastatic breast cancer. Target potential partnerships with contract research organizations, academic collaborators, and oncology/neurology consortia to accelerate clinical development, share risk, and expand access to specialized trial networks and registrational studies.

Late-stage Opportunity The company is advancing a Phase 3 program for Lasofoxifene in ESR1-mutated metastatic breast cancer and anticipates topline data in 2H 2027. This presents a near-term opportunity for potential licensing, co-development, or strategic investment aligned with multi-billion dollar market potential in ER-positive/HER2-negative breast cancer.

ALS Expansion With ATH-1105 progressing toward ALS-focused trials and multiple ALS-focused events, there is a clear avenue for collaborations around biomarker development, patient recruitment networks, and payer/health economics partnerships to support proof-of-concept results and eventual commercialization.

Clinical Capabilities LeonaBio's mix of phase 2/3 assets and recent board enhancements signal readiness for strategic financing rounds, licensing discussions, or co-commercialization deals. Engage in conversations around capital raises, milestone-based licensing, and strategic advisory to scale clinical operations and international trials.

Market Readiness With a strong investor profile (NASDAQ: LONA), substantial funding, and ongoing high-profile conference participation, there are opportunities to position ancillary services, CRO collaborations, and regulatory consulting packages to support rapid clinical milestones, data disclosures, and eventual market entry strategies.